The Buffalo-Niagara Clinical Alliance.

05/29/2015

For the performance of a site in a clinical trial, the number of publications of the investigator is not a truly hard parameter. The set up of a site and its performance in previous trials (especially recruitment capabilities) are much more important for the success of a trial.

04/20/2015

BNCA provide clinical trial service activities that are dedicated to running and managing the clinical site for a larger CRO (clinical research organization) or sponsors or trial sites. Our risk-Based Monitoring (RBM) is an innovative strategy for managing risk that concentrates attention on those a…

03/27/2015

Informed consent is more than just a signature on a form, it is a process of information exchange that may include, in addition to reading and signing the informed consent document, subject recruitment materials, verbal instructions, question/answer sessions and measures of subject understanding. In…

03/19/2015

Mobile apps and tablets take over clinical-trials!! The mobile,tablet and “apps” market have been growing rapidly and steadily for the past few years. With the introduction of the iPad in 2010, the tablet market is gaining attention as product value soars in many industries. Health and pharmaceutica…

03/15/2015

Today we had an exciting and productive meeting with a group of physicians and their administrators at GBUAHN. SO you might wonder what this is all about? Well… GBUAHN is an organization that provides and fulfills a vital need in our society – taking care of those who need medical care the most.…

01/17/2015

Please find us in Buffalo News!!
http://www.buffalonews.com/city-region/on-the-record-dec-26-2014-20141225

Evolution Dental Science named Colin Chiarmonte crown and bridge fabrication specialist. Chiarmonte returned to EDS after working at Global Dental Science in Arizona for four years. Also EDS named Vinnie Murphy implant adviser. Murphy returned to EDS after working at Voss Dental, New Creation Dental…

12/20/2014

Viekira is out in the market.
$83,319 for a twelve week course of therapy. $94,500 for twelve weeks of Harvoni. Twelve weeks of Sovaldi/Olysio $150,360 (84,000 plus 66,360).
http://www.wsj.com/articles/fda-approves-abbvies-hepatitis-treatment-1419019392

U.S. regulators on Friday approved AbbVie Inc.’s new multidrug regimen for hepatitis C, the latest in a wave of new medicines that is transforming treatment of the liver disease.

12/13/2014

12/03/2014

We are getting ready to meet a new group of clinical professionals to discuss more about our service and how we can help them to get their site up and running. Very exciting!!!